Related Experiment Videos
CD30 expression is common in mediastinal large B-cell lymphoma.
1Department of Pathology, Stanford University Medical Center, CA 94305, USA.
American Journal of Clinical Pathology
|August 10, 1999
Summary
Primary mediastinal large B-cell lymphoma often expresses CD30, a marker typically associated with Hodgkin lymphoma. This finding highlights a potential diagnostic challenge, emphasizing the need for careful evaluation to avoid misclassification.
Area of Science:
- Hematology
- Oncology
- Immunopathology
Background:
- Primary mediastinal large B-cell lymphoma (PMLBCL) is a distinct entity with unique clinical and immunophenotypic characteristics.
- PMLBCL is recognized as a unique subtype within the Revised European-American Lymphoma classification.
- Distinguishing PMLBCL from other lymphomas is crucial for appropriate treatment and prognosis.
Purpose of the Study:
- To investigate the expression of CD30 in a cohort of primary mediastinal large B-cell lymphoma cases.
- To assess the frequency and pattern of CD30 positivity in PMLBCL.
- To evaluate the potential for CD30 expression to cause diagnostic confusion with Hodgkin lymphoma.
Main Methods:
- Retrospective analysis of 51 cases of primary mediastinal large B-cell lymphoma.
- Immunohistochemical staining using anti-CD30 (Ber-H2) antibody.
- Evaluation of staining intensity and distribution on neoplastic cells.
Main Results:
- CD30 expression was observed in 35 out of 51 cases (69%) of PMLBCL.
- Staining patterns varied from strong and widespread to focal positivity.
- Eleven cases (22%) were negative for CD30, and 4 (8%) showed equivocal results.
Conclusions:
- The majority of primary mediastinal large B-cell lymphomas express CD30.
- CD30 positivity in PMLBCL can mimic Hodgkin lymphoma, posing a diagnostic challenge.
- Awareness of CD30 expression in PMLBCL is essential for accurate diagnosis and to prevent misdiagnosis as Hodgkin disease.